Gilead’s remdesivir could see $7 billion in annual sales on stockpiling boost: analyst

Why don’t people trust companies? 7 billion reasons projected in profiteering gains…

?m=02&d=20200603&t=2&i=1520963980&w=1200

Gilead Sciences Inc’s potential COVID-19 treatment, remdesivir, could bring in more than $7 billion in annual sales by 2022, spurred by governments stockpiling the drug to guard against future outbreaks, SVB Leerink said on Wednesday.

topNews?d=yIl2AUoC8zA topNews?i=ODexvvKB--o:812A0dl8Yl4:V_sGLi topNews?i=ODexvvKB--o:812A0dl8Yl4:-BTjWO